Genetic Signatures (GSS) Stock Price, News & Analysis

Company Overview

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$120.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GSS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Genetic Signatures own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genetic Signatures investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU), VelocityShares 1x Long VSTOXX Futures ETN (EVIX) and First Trust United Kingdom AlphaDEX Fund (FKU).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: ASX:GSS
• CIK: N/A
• Web: www.geneticsignatures.com
• Phone: 61 2 9870 7580
• Fax: N/A
• Employees: 1,626
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$17.86 million
• Net Margins: -182.90%
• Pretax Margin: N/A
• Return on Equity: -35.16%
• Return on Assets: -19.69%

Debt

• Debt-to-Equity Ratio: 2.00
• Current Ratio: 10.04
• Quick Ratio: 8.54

Sales & Book Value

• Annual Sales: A$13.77 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.29 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 226,870,000
• Free Float: N/A
• Market Cap: A$120.38 million
• Optionable: Not Optionable
• Beta: 0.05